Crescent Innovations announced the sale of its technology related to bone regeneration, plus various intellectual property and know-how assets.
The ability to grow bone at a site-specific location, in a minimally invasive manner, would have a profound impact on the health and quality of life for up to 50 million Americans who suffer bone defects and diseases. These diseases include post-craniotomy resorption, periodontal disease, degenerative disc disease, osteoporosis and aseptic osteolysis. Together, these diseases cost the United States Healthcare System in excess of $124 billion annually.
The state of the art is Bone Morphogenic Proteins (BMPs) which are osteogenic compounds. However, BMPs can cause heterotopic ossification (bone growth at non-boney sites), which makes them somewhat difficult and risky to use.
The invention comprises a patented osteogenic formulation of prostaglandin E1, an already approved drug, and a delivery system (HA or Crescent Innovations’ patented PgGA). This technology has been shown to grow bone rapidly in vivo without inducing bone synthesis at ectopic sites by non-bone cells.
The assets will be sold at a sealed bid sale on June 28, 2024 at 12 PM EDT.
Crescent Innovations announced the sale of its technology related to bone regeneration, plus various intellectual property and know-how assets.
The ability to grow bone at a site-specific location, in a minimally invasive manner, would have a profound impact on the health and quality of life for up to 50 million Americans who suffer bone...
Crescent Innovations announced the sale of its technology related to bone regeneration, plus various intellectual property and know-how assets.
The ability to grow bone at a site-specific location, in a minimally invasive manner, would have a profound impact on the health and quality of life for up to 50 million Americans who suffer bone defects and diseases. These diseases include post-craniotomy resorption, periodontal disease, degenerative disc disease, osteoporosis and aseptic osteolysis. Together, these diseases cost the United States Healthcare System in excess of $124 billion annually.
The state of the art is Bone Morphogenic Proteins (BMPs) which are osteogenic compounds. However, BMPs can cause heterotopic ossification (bone growth at non-boney sites), which makes them somewhat difficult and risky to use.
The invention comprises a patented osteogenic formulation of prostaglandin E1, an already approved drug, and a delivery system (HA or Crescent Innovations’ patented PgGA). This technology has been shown to grow bone rapidly in vivo without inducing bone synthesis at ectopic sites by non-bone cells.
The assets will be sold at a sealed bid sale on June 28, 2024 at 12 PM EDT.
Copy to clipboard 
